Cancer
Survivin 96-104 (HLA-A*02:01) LMLGEFLKL
Product number: EP11422_5
€210.00*
Prices excl. VAT plus shipping
costs
Available, delivery time:
1-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity:
95% HPLC-MS
Caution:
For research use only. Not for use in humans.
Amount in mg
1
Description
LMLGEFLKL is a linear peptidic epitope (epitope ID38060), tested in T cell assays. The vector of anti-Survivin T cell receptor (TCR) is constructed for the engineering of T cell to target Human Survivin. The T cells are genetically modified through transduction with a retroviral vector expressing Survivin-specific T cell receptor. And the vector product was designed for the treatment of diseases involving malignant cells expressing survivin.
TechData
| Sequence: | LMLGEFLKL |
| Delivery: | 1-3 days |
| C-Terminus: | OH |
| N-Terminus: | H |
| Amount: | 1 mg |
| Counterion: | TFA |
| Protein: | Survivin |
| Species: | Human |
| Allele: | HLA-A*02:01 |
| Application: | Cellular immune response, Immune monitoring, T-cell assays, Immunohistochemistry |
| Indication: | Cancer |
| Purity: | 95% HPLC-MS |